Lau Sally C, Cheung Winson Y
Sally C Lau, Division of Medical Oncology, University of British Columbia, British Columbia Cancer Agency, Vancouver, BC V5Z 4E6, Canada.
World J Gastrointest Oncol. 2017 Jul 15;9(7):281-292. doi: 10.4251/wjgo.v9.i7.281.
Pancreatic ductal adenocarcinoma is an infrequent cancer with a high disease related mortality rate, even in the context of early stage disease. Until recently, the rate of death from pancreatic cancer has remained largely similar whereby gemcitabine monotherapy was the mainstay of systemic treatment for most stages of disease. With the discovery of active multi-agent chemotherapy regimens, namely FOLFIRINOX and gemcitabine plus nab-paclitaxel, the treatment landscape of pancreatic cancer is slowly evolving. FOLFIRINOX and gemcitabine plus nab-paclitaxel are now considered standard first line treatment options in metastatic pancreatic cancer. Studies are ongoing to investigate the utility of these same regimens in the adjuvant setting. The potential of these treatments to downstage disease is also being actively examined in the locally advanced context since neoadjuvant approaches may improve resection rates and surgical outcomes. As more emerging data become available, the management of pancreatic cancer is anticipated to change significantly in the coming years.
胰腺导管腺癌是一种罕见的癌症，即使在疾病早期，其疾病相关死亡率也很高。直到最近，胰腺癌的死亡率在很大程度上仍保持相似，吉西他滨单药治疗是大多数疾病阶段全身治疗的主要手段。随着多药联合化疗方案（即FOLFIRINOX和吉西他滨加纳米白蛋白结合型紫杉醇）的发现，胰腺癌的治疗格局正在缓慢演变。FOLFIRINOX和吉西他滨加纳米白蛋白结合型紫杉醇现在被认为是转移性胰腺癌的标准一线治疗选择。正在进行研究以探讨这些相同方案在辅助治疗中的效用。由于新辅助治疗方法可能提高切除率和手术效果，这些治疗使疾病降期的潜力也正在局部晚期的情况下积极研究。随着越来越多的新数据出现，预计未来几年胰腺癌的管理将发生重大变化。
